Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPINASDAQ:IMTXNASDAQ:LENZNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPICheckmate Pharmaceuticals$10.50$10.46$2.00▼$10.50$231.40M-4.81142,261 shsN/AIMTXImmatics$5.11-1.7%$4.52$3.30▼$13.77$621.12M0.87659,209 shs375,092 shsLENZLENZ Therapeutics$28.17-0.2%$25.45$14.42▼$38.93$792.87M0.41184,124 shs84,858 shsREPLReplimune Group$8.35-4.7%$8.63$4.92▼$17.00$643.08M0.68926,127 shs1.46 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPICheckmate Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IMTXImmatics-1.73%+7.81%+13.30%+11.09%-50.58%LENZLENZ Therapeutics-0.18%+5.07%+4.53%+19.92%+53.01%REPLReplimune Group-4.68%+6.37%-5.65%-40.27%+40.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIMTXImmatics2.8198 of 5 stars3.64.00.00.03.61.70.0LENZLENZ Therapeutics1.9254 of 5 stars3.60.00.00.03.72.50.0REPLReplimune Group3.9964 of 5 stars3.60.00.04.53.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPICheckmate Pharmaceuticals 0.00N/AN/AN/AIMTXImmatics 3.25Buy$17.00232.68% UpsideLENZLENZ Therapeutics 3.17Buy$46.6065.42% UpsideREPLReplimune Group 3.13Buy$19.43132.68% UpsideCurrent Analyst Ratings BreakdownLatest CMPI, LENZ, REPL, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.003/18/2025LENZLENZ TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.002/26/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPICheckmate PharmaceuticalsN/AN/AN/AN/A$2.50 per shareN/AIMTXImmatics$144.15M4.31N/AN/A$2.88 per share1.77LENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPICheckmate Pharmaceuticals-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/AIMTXImmatics-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%8/12/2025 (Estimated)LENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%N/AREPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)Latest CMPI, LENZ, REPL, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPICheckmate PharmaceuticalsN/A5.205.20IMTXImmaticsN/A3.983.98LENZLENZ TherapeuticsN/A28.6328.63REPLReplimune Group0.1411.4311.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPICheckmate Pharmaceuticals74.56%IMTXImmatics64.41%LENZLENZ Therapeutics54.32%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipCMPICheckmate Pharmaceuticals62.60%IMTXImmatics3.30%LENZLENZ Therapeutics38.40%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPICheckmate Pharmaceuticals2822.04 million8.24 millionNot OptionableIMTXImmatics260121.55 million115.42 millionOptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/AREPLReplimune Group21077.02 million70.24 millionOptionableCMPI, LENZ, REPL, and IMTX HeadlinesRecent News About These CompaniesReplimune Group (NASDAQ:REPL) Shares Gap Up - Here's WhyMay 24 at 10:55 AM | marketbeat.comTraders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)May 24 at 10:55 AM | marketbeat.comEarnings call transcript: Replimune Q1 2025 sees stock drop post-earningsMay 24 at 3:40 AM | uk.investing.comREPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly EarningsMay 24 at 3:40 AM | nasdaq.comReplimune Group Sees Unusually Large Options Volume (NASDAQ:REPL)May 24 at 1:35 AM | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call TranscriptMay 23 at 9:05 AM | insidermonkey.comEmily Luisa Hill Sells 2,535 Shares of Replimune Group, Inc. (NASDAQ:REPL) StockMay 23 at 8:22 AM | insidertrades.comPoint72 Asset Management L.P. Buys Shares of 283,966 Replimune Group, Inc. (NASDAQ:REPL)May 23 at 4:36 AM | marketbeat.comQ4 2025 Replimune Group Inc Earnings CallMay 23 at 12:51 AM | uk.finance.yahoo.comReplimune Group, Inc. (REPL) Q4 2025 Earnings Call TranscriptMay 22 at 12:01 PM | seekingalpha.comReplimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateMay 22 at 7:00 AM | globenewswire.comNorthern Trust Corp Acquires 40,134 Shares of Replimune Group, Inc. (NASDAQ:REPL)May 22 at 3:07 AM | marketbeat.comVelan Capital Investment Management LP Acquires Shares of 181,367 Replimune Group, Inc. (NASDAQ:REPL)May 21 at 8:23 AM | marketbeat.comSoleus Capital Management L.P. Acquires Shares of 262,500 Replimune Group, Inc. (NASDAQ:REPL)May 21 at 8:13 AM | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Stock Holdings Lifted by Tang Capital Management LLCMay 20, 2025 | marketbeat.comRTW Investments LP Grows Stake in Replimune Group, Inc. (NASDAQ:REPL)May 18, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 10.9% - What's Next?May 18, 2025 | americanbankingnews.comReplimune Group: Analysts Are More Optimistic Than The MarketMay 16, 2025 | seekingalpha.com950,000 Shares in Replimune Group, Inc. (NASDAQ:REPL) Purchased by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $10.53 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)May 16, 2025 | marketbeat.comReplimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor DayMay 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPI, LENZ, REPL, and IMTX Company DescriptionsCheckmate Pharmaceuticals NASDAQ:CMPICheckmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Immatics NASDAQ:IMTX$5.11 -0.09 (-1.73%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.12 +0.01 (+0.20%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.LENZ Therapeutics NASDAQ:LENZ$28.17 -0.05 (-0.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$28.76 +0.58 (+2.08%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Replimune Group NASDAQ:REPL$8.35 -0.41 (-4.68%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.65 +0.30 (+3.59%) As of 05/23/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
